» Articles » PMID: 26137283

Rapid and Early α-fetoprotein and Des-γ-carboxy Prothrombin Responses to Initial Arterial Infusion Chemotherapy Predict Treatment Outcomes of Advanced Hepatocellular Carcinoma

Abstract

The aim of the present study was to predict the effects of transarterial infusion (TAI) chemotherapy based on early changes in α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) in patients with advanced hepatocellular carcinoma (HCC). Seventy-four patients who underwent TAI with cisplatin, 5-fluorouracil, mitomycin C and epirubicin for advanced HCC were enrolled. Antitumor responses were evaluated 6 months after TAI. Rapid and early responses were defined as the ratio of AFP or DCP after 1 week and 1 month compared to baseline. A total of 5, 10, 17 and 42 patients had complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), respectively. Early AFP response was significantly lower in the CR+PR compared to the SD+PD groups (P<0.01). The early DCP response was significantly lower in the CR+PR compared to the SD+PD. The sensitivity and specificity of rapid and early AFP responses in the CR+PR were 0.78 and 0.72, and 0.80 and 0.73, respectively, and those of rapid and early DCP responses were 0.67 and 0.65, and 0.77 and 0.71, respectively. The combination of AFP and DCP responses had higher specificity compared to AFP or DCP alone responses. Patients were divided into responder and non-responder groups to evaluate the prediction of survival outcome. Early responders of AFP, DCP and AFP+DCP, who were divided based on the cut-off values of CR+PR survived significantly longer than the non-responders (P<0.05). In conclusion, rapid or early responses of AFP and/or DCP levels 1 and 4 weeks after TAI chemotherapy helped to predict the treatment effects.

Citing Articles

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation.

Yao C, Wang J, Chen C, Hung C, Yen Y, Kee K Diagnostics (Basel). 2023; 13(4).

PMID: 36832184 PMC: 9955975. DOI: 10.3390/diagnostics13040696.

References
1.
Kishi K, Sonomura T, Mitsuzane K, Nishida N, Kimura M, Satoh M . Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Radiat Med. 1992; 10(5):189-95. View

2.
Blum H . Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2006; 11(47):7391-400. PMC: 4725160. DOI: 10.3748/wjg.v11.i47.7391. View

3.
Bellet D, Wands J, Isselbacher K, Bohuon C . Serum alpha-fetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci U S A. 1984; 81(12):3869-73. PMC: 345323. DOI: 10.1073/pnas.81.12.3869. View

4.
Chen L, Liu T, Chao Y, Shiah H, Chang J, Juang S . alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2005; 22(3):217-26. DOI: 10.1111/j.1365-2036.2005.02547.x. View

5.
Worns M, Weinmann A, Pfingst K, Schulte-Sasse C, Messow C, Schulze-Bergkamen H . Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009; 43(5):489-95. DOI: 10.1097/MCG.0b013e31818ddfc6. View